

Malaysia Thailand Collaboration to Increase the Affordability and Accessibility of Cancer Drugs in Thailand Through Local Manufacturing

SHAH ALAM, SELANGOR, MALAYSIA, July 30th, 2021 - Novugen Oncology Sdn Bhd (formerly known as Oncogen Pharma) has announced entering a strategic collaboration with Thailand's Chulabhorn Royal Academy to provide its technology for key cancer drugs to be manufactured in Thailand.

The collaboration is directed to transfer the technology and know-how from Novugen Oncology global R&D center in Malaysia to Chulabhorn manufacturing facility in Thailand. This collaboration aims to develop a level of competency in R&D, and manufacturing of prescription drugs to help millions of cancer patients in ASEAN region.



Illustration of Novugen Oncology Plant in Bandar Enstek Park, Negeri Sembilan, Malaysia



Chulabhorn Royal Academy Plant in Chon Buri, Thailand

The Chulabhorn project runs under an initiative and the wishes of Professor Dr. Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana, who believes that cancer is a critical public health issue. Recognizing the need to address this concern, the project is aimed to provide accessibility and affordability of cancer treatments.

Rahil Mahmood, Chief Executive Officer, of Novugen Oncology expressed his desire to work on future collaborations with Chulabhorn Royal academy, “We are honoured to enter into a collaboration with Chulabhorn Royal Academy and hope that the combination of the two companies’ development and manufacturing capabilities will bring in affordable and innovative cancer drugs to patients not only in Thailand but the whole ASEAN region”.

According to the collaboration terms, the three main cancer medicines are targeting lung cancer, leukaemia and pancreatic cancer, will result in manufacturing of these drugs in Thailand within the next 3 years. Both companies fully expect this collaboration to expand significantly in future to bring in all major cancer treatments under it.

For more information about this collaboration or for any requests to explore partnership with Novugen Oncology, please contact Dr. Sabrina Lee at sabrina.lee@novugen.com.

About Novugen

Novugen is a wholly owned subsidiary company of a UAE based group with more than 30 years of experience in strategic healthcare businesses and development of world class healthcare facilities around the globe. Novugen's globally minded strategy, synergistic approach and wealth of experience enable us to respond to the complex challenge of bringing hard-to-source and technology-intensive products to market while maintaining affordable pricing and rigorous quality assurance. As a technology leader, we create efficiency by integrating our total value chain. At Novugen, our science and business teams work together seamlessly to innovate new concepts and fresh ideas to accelerate the launch of pharmaceuticals that lack robust generic alternatives due to their complexity.

Website: www.novugen.com

About Chulabhorn Royal Academy Thailand

Chulabhorn Royal Academy (CRA) is a non-profit Institution/Organization founded by Professor Dr. Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana in Thailand. Aspired to carry on the commitment of His Majesty King Bhumibol Adulyadej's dedication to improving the well-being of people living in Thailand. CRA is one of the leading learning and research centre in the fields of medicine, science, public health, and environment management. Additionally, CRA provides medical services of international quality standards for the general public, particularly in the poor and the underprivileged, in honour of His Majesty King Bhumibol Adulyadej's dedication.

Under the initiative of Professor Dr. Her Royal Princess Chulabhorn, Chulabhorn Hospital was expanded to encompass HRH Princess Chulabhorn College of Medical Science comprising of Bhadra Maharajanusorn Medical Centre, Chulabhorn Oncology Medical

Press Statement



Centre and Chulabhorn Chalermpakiet Medical Center. Furthermore, a post-graduate academic institution, Chulabhorn Graduate Institute, and an oncology manufacturing plant, Chulabhorn Royal Pharmaceutical Manufacturing Facility, were established. All the centers and institutions were unified and engaged in full cooperation under the name of Chulabhorn Royal Academy.

Source:

<https://apnews.com/press-release/PRcom/business-science-health-malaysia-thailand-39ed481fdff2863cebcd6a22e308b18f>